Novo Nordisk has published data in The Lancet and presented findings at the American Diabetes Association (ADA) Scientific Sessions regarding its investigational treatment, amycretin. This treatment is designed for people with overweight or obesity, combining GLP-1 and amylin receptor agonism biology into a single molecule.
The results from the phase 1b/2a clinical trial of subcutaneous amycretin indicated significant weight loss among participants compared to those receiving a placebo. “No plateauing in weight reduction was observed at the end of treatment,” according to Novo Nordisk’s findings. Adverse events were mainly gastrointestinal, mild to moderate in severity, and resolved by the study’s end.
In parallel, the oral amycretin phase 1 trial showed promising results. Participants achieved greater weight loss compared to placebo without apparent signs of plateauing during the 12-week period. The safety profile was consistent with expectations for targeting GLP-1 and amylin receptors.
Martin Holst Lange, executive vice president for Development at Novo Nordisk, commented on these developments: “As pioneers in obesity innovation, we are exploring multiple biological pathways… The findings published and presented today are encouraging.”
Following these trials, Novo Nordisk plans to advance amycretin into phase 3 trials to further evaluate its potential as a therapeutic option for weight management.
Amycretin is being developed for both subcutaneous and oral administration as an effective treatment for adults with overweight or obesity and type 2 diabetes. Novo Nordisk is committed to expanding access to innovative treatments while addressing chronic diseases like diabetes globally.
For more information about Novo Nordisk’s work and updates on amycretin’s development, visit their official website or social media platforms.
